AI Article Synopsis
- There is a pressing need for new strategies to achieve immune tolerance in transplant recipients and autoimmune patients without relying on long-term immunosuppression.
- Adoptive T regulatory cell (T) therapy shows promise for providing durable protection, but current clinical trials suggest that simply infusing expanded autologous T cells isn't showing significant benefits on its own.
- Combining T cell therapy with additional treatments that support stable donor T cell engraftment and function may enhance outcomes and lead to longer-lasting therapeutic effects.
Article Abstract
There is a clear need to develop strategies to induce tolerance without the need of chronic immunosuppression in transplant recipient and in patients with autoimmunity. Adoptive T regulatory cell (T) therapy offers the potential of long-lasting protection. However, based on results of clinical trials so far with expanded autologous T in type 1 diabetic (T1D) patients, it seems unlikely that single immunotherapy with T infusion without immunomodulation regimens that promote stable donor T engraftment and persistence would afford truly significant clinical benefit. Combination therapies could provide improved outcomes with consideration of the fundamental factors required for T generation, homeostasis, and function to promote long-term donor T persistence to provoke beneficial therapeutic outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415881 | PMC |
| http://dx.doi.org/10.1007/s40472-015-0058-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!